Graham Smith

Graham Smith

Auto-generated profile, based on publicly available information

Graham Smith

Division of Radiotherapy and Imaging, The Institute of Cancer Research, 123 Old Brompton Road, London, UK.

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2009 in Proceedings of the National Academy of Sciences of the United States of America
Verified
Journal Article
Closed access
PDF file
QNQuang-Dé Nguyen
Quang-Dé Nguyen
GSGraham Smith
Graham Smith
MGMatthias Glaser
Matthias Glaser
MPMeg Perumal
Meg Perumal
EAErik Arstad
Erik Arstad
EAEric Ofori Aboagye
Eric Ofori Aboagye
Of the molecular biochemical alterations that occur during apoptosis, activation of caspases, notably caspase-3, is probably the most attractive for developing specific in vivo molecular imaging probes. We recently designed a library of isatin-5 sulfonamides and selected [ 18 F]ICMT-11 for further evaluation on the basis of subnanomolar affinity for activated capsase-3, high metabolic stability, and facile radiolabeling. In this present study, we have demonstrated that [ 18 F]ICMT-11 binds to a range of drug-induced apoptotic cancer cells in vitro and to 38C13 murine lymphoma xenografts in vivo by up to 2-fold at 24 h posttreatment compared to vehicle treatment. We further demonstrated that the increased signal intensity in tumors after drug treatment, detected by whole body in vivo microPET imaging, was associated with increased apoptosis. In summary, we have characterized [ 18 F]ICMT-11 as a caspase-3/7 specific PET imaging radiotracer for the assessment of tumor apoptosis that could find utility in anticancer drug development and the monitoring of early responses to therapy.

2 December 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GSGraham Smith
Graham Smith
MGMatthias Glaser
Matthias Glaser
MPMeg Perumal
Meg Perumal
QNQuang-De Nguyen
Quang-De Nguyen
BSBo Shan
Bo Shan
EAEric Ofori Aboagye
Eric Ofori Aboagye

30 March 2020 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
Adam SedgwickAdam Sedgwick
Adam Sedgwick
JBJames Brewster
James Brewster
PHPeter Harvey
Peter Harvey
DIDiana A. Iovan
Diana A. Iovan
GSGraham Smith
Graham Smith
Tony D. JAMESTony D. JAMES
Tony D. JAMES
Central nervous system (CNS) neurodegeneration is defined by a complex series of pathological processes that ultimately lead to death. The precise etiology of these disorders remains unknown. Recent efforts show that a mechanistic understanding of the malfunctions underpinning disease progression will prove requisite in developing new treatments and cures. Transition metals and lanthanide ions display unique characteristics (i.e., magnetism, radioactivity, and luminescence), often with biological relevance, allowing for direct application in CNS focused imaging modalities. These techniques include positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and luminescent-based imaging (LumI). In this Tutorial Review, we have aimed to highlight the various metal-based imaging techniques developed in the effort to understand the pathophysiological processes associated with neurodegeneration. Each section has been divided so as to include an introduction to the particular imaging technique in question. This is then followed by a summary of key demonstrations that have enabled visualization of a specific neuropathological biomarker. These strategies have either exploited the high binding affinity of a receptor for its corresponding biomarker or a specific molecular transformation caused by a target species, all of which produce a concomitant change in diagnostic signal. Advantages and disadvantages of each method with perspectives on the utility of molecular imaging agents for understanding the complexities of neurodegenerative disease are discussed.

19 July 2016 in Bioconjugate Chemistry
Verified
Journal Article
Open access
CPChiara Da Pieve
Chiara Da Pieve
LALouis Allott
Louis Allott
CMCarlos D. Martins
Carlos D. Martins
AVAndrew Vardon
Andrew Vardon
DCDaniela M. Ciobota
Daniela M. Ciobota
GSGraham Smith
Graham Smith
The human epidermal growth factor receptor 3 (HER3) is overexpressed in several cancers, being linked to a more resistant phenotype and hence leading to poor patient prognosis. Imaging HER3 is challenging owing to the modest receptor number (<50000 receptors/cell) in overexpressing cancer cells. Therefore, to image HER3 in vivo, high target affinity PET probes need to be developed. This work describes two different [18F]AlF radiolabeling strategies of the ZHER3:8698 affibody molecule specifically targeting HER3. The one-pot radiolabeling of ZHER3:8698 performed at 100 °C and using 1,4,7-triazanonane-1,4,7-triacetate (NOTA) as chelator resulted in radiolabeled products with variable purity attributed to radioconjugate thermolysis. An alternative approach based on the inverse electron demand Diels–Alder (IEDDA) reaction between a novel tetrazine functionalized 1,4,7-triazacyclononane-1,4-diacetate (NODA) chelator and the trans-cyclooctene (TCO) functionalized affibody molecule was also investigated. This method enabled the radiolabeling of the protein at room temperature. The [18F]AlF-NOTA-ZHER3:8698 and [18F]AlF-NODA-ZHER3:8698 conjugates showed a specific uptake at 1 h after injection in high HER3-expressing MCF-7 tumors of 4.36 ± 0.92% ID/g and 4.96 ± 0.65% ID/g, respectively. The current results are encouraging for further investigation of [18F]AlF-NOTA-ZHER3:8698 as a HER3 imaging agent.

14 February 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TWTimothy H Witney
Timothy H Witney
IAIsrat S. Alam
Israt S. Alam
DTDavid R. Turton
David R. Turton
GSGraham Smith
Graham Smith
LCLaurence Carroll
Laurence Carroll
EAEric Ofori Aboagye
Eric Ofori Aboagye
Purpose: 11C-Choline–positron emission tomography (PET) has been exploited to detect the aberrant choline metabolism in tumors. Radiolabeled choline uptake within the imaging time is primarily a function of transport, phosphorylation, and oxidation. Rapid choline oxidation, however, complicates interpretation of PET data. In this study, we investigated the biologic basis of the oxidation of deuterated choline analogs and assessed their specificity in human tumor xenografts. Experimental Design: 11C-Choline, 11C-methyl-[1,2-2H4]-choline (11C-D4-choline), and 18F-D4-choline were synthesized to permit comparison. Biodistribution, metabolism, small-animal PET studies, and kinetic analysis of tracer uptake were carried out in human colon HCT116 xenograft–bearing mice. Results: Oxidation of choline analogs to betaine was highest with 11C-choline, with reduced oxidation observed with 11C-D4-choline and substantially reduced with 18F-D4-choline, suggesting that both fluorination and deuteration were important for tracer metabolism. Although all tracers were converted intracellularly to labeled phosphocholine (specific signal), the higher rate constants for intracellular retention (Ki and k3) of 11C-choline and 11C-D4-choline, compared with 18F-D4-choline, were explained by the rapid conversion of the nonfluorinated tracers to betaine within HCT116 tumors. Imaging studies showed that the uptake of 18F-D4-choline in three tumors with similar radiotracer delivery (K1) and choline kinase α expression—HCT116, A375, and PC3-M—were the same, suggesting that 18F-D4-choline has utility for cancer detection irrespective of histologic type. Conclusion: We have shown here that both deuteration and fluorination combine to provide protection against choline oxidation in vivo. 18F-D4-choline showed the highest selectivity for phosphorylation and warrants clinical evaluation. Clin Cancer Res; 18(4); 1063–72. ©2012 AACR.

1 March 2012 in European Journal of Cancer
Verified
Journal Article
Closed access
QNQuang-Dé Nguyen
Quang-Dé Nguyen
ACAmarnath Challapalli
Amarnath Challapalli
GSGraham Smith
Graham Smith
RFRobin Fortt
Robin Fortt
EAEric Ofori Aboagye
Eric Ofori Aboagye